Multivariate Cox PH analysis (see supplemental Appendix) of predictors of VTE recurrence among Olmsted County residents with active cancer-related incident DVT or PE, 1966-2000
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Stage IV pancreatic cancer* | 6.38 | 2.69, 15.13 | <.0001 |
| Brain cancer* | 4.57 | 2.07, 10.09 | .0002 |
| Myeloproliferative or myelodysplastic disorder* | 3.49 | 1.59, 7.68 | .002 |
| Ovarian cancer* | 3.22 | 1.57, 6.59 | .001 |
| Stage IV cancer (non pancreas)* | 2.85 | 1.74, 4.67 | <.0001 |
| Lung cancer* | 2.73 | 1.63, 4.55 | .0001 |
| Neurological disease with leg paresis | 2.38 | 1.14, 4.97 | .02 |
| Cancer stage progression | 2.14 | 1.30, 3.52 | .003 |
| Multiple active cancers | 1.78 | 0.87, 3.63 | .12 |
| Gastrointestinal (noncolorectal) cancer* | 1.94 | 0.90, 4.17 | .09 |
| Stage III cancer, ALL or AML* | 1.47 | 0.95, 2.27 | .09 |
| Warfarin therapy | 0.43 | 0.28, 0.66 | <.0001 |
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Stage IV pancreatic cancer* | 6.38 | 2.69, 15.13 | <.0001 |
| Brain cancer* | 4.57 | 2.07, 10.09 | .0002 |
| Myeloproliferative or myelodysplastic disorder* | 3.49 | 1.59, 7.68 | .002 |
| Ovarian cancer* | 3.22 | 1.57, 6.59 | .001 |
| Stage IV cancer (non pancreas)* | 2.85 | 1.74, 4.67 | <.0001 |
| Lung cancer* | 2.73 | 1.63, 4.55 | .0001 |
| Neurological disease with leg paresis | 2.38 | 1.14, 4.97 | .02 |
| Cancer stage progression | 2.14 | 1.30, 3.52 | .003 |
| Multiple active cancers | 1.78 | 0.87, 3.63 | .12 |
| Gastrointestinal (noncolorectal) cancer* | 1.94 | 0.90, 4.17 | .09 |
| Stage III cancer, ALL or AML* | 1.47 | 0.95, 2.27 | .09 |
| Warfarin therapy | 0.43 | 0.28, 0.66 | <.0001 |
The patients were followed-up through December 31, 2005. For all variables, the referent group is without the risk factor, except where indicated.
The comparison group included stage I/stage II cancers of the prostate, breast, other gynecologic, colon-rectal, kidney, bladder, other genitourinary, and other cancer, as well as lymphoma, chronic myelocytic leukemia, and multiple myeloma.